Federal Medicare officials are embracing medical guidelines for the treatment of hepatitis C that could result in tens of thousands of older Americans getting access to expensive new drugs that can cure the deadly infection This policy change would pay for treatment with a combination of new expensive drugs for patients who havent responded to older treatment regimens and are approaching or have cirrhosis of the liver The shift has come about because of an Arizona man named Walter Bianco who was twice denied Medicare coverage for two new drugs that together cost about  But those denials were reversed this week after Shots and NPRs     on Biancos case Bianco has been infected with hepatitis C for  years and the virus has taken a toll on his liver In a statement late Wednesday   deputy administrator of the Centers for Medicare and Medicaid Services said the reversal resulted from updated treatment guidelines that recommend the use of the new drugs   and   for patients in Biancos case  even though the combination treatment hasnt been approved by the Food and Drug Administration Before now Medicare hadnt explicitly embraced the treatment guidelines that were issued in January by the   and the American Association for the Study of Liver Diseases They say that patients who havent been cured by older regimens should be considered for treatment with Sovaldi plus Olysio Together they cost about   a price tag that has alarmed health insurers and government payers and worried doctors who fear that lifesaving medications could be withheld from hepatitis C patients Medicare officials note that under the programs Part D drug coverage beneficiaries who have a medical need for drugs and meet medically accepted indications are required to have access to needed therapies The implication is that medically accepted indications includes treatment guidelines from outside medical groups An estimated  million to  million Americans are infected with hepatitis C a virus that can take decades to cause significant liver damage But once it does patients are at high risk of liver failure requiring transplantation or liver cancer Most people with hepatitis C dont know they have it The Centers for Disease Control and Prevention   that all Americans born between  and  be tested for the virus a step that is expected to increase demand for the new treatments  of the National Viral Hepatitis Roundtable a patient advocacy group says Medicares new stance on paying for new hepatitis C treatments will have a big impact This is a really positive step he tells Shots A lot of people with hepC are in Medicare or will be soon Private plans that administer Medicare drug benefits may still deny coverage of unapproved regimens such as Sovaldi and Olysio But Clary says the new federal stance suggests patients might be more likely to prevail on appeal Medicare coverage of the new drugs alone or in combination is expected to have enormous cost implications Last week Cavanaugh acknowledged the cost impact in an address before a US Chamber of Commerce According to an account by   Cavanaugh says the agency wont know how big an effect it will have until later this year Gilead Sciences which makes Sovaldi has reported that  percent of its  billion in firstquarter US sales went to patients covered by Medicare or commercial health plans  says One clue to the possible impact will come in the next few weeks when health plans that participate in Part D submit bids to Medicare for next year